Zoetis Inc. (ZTS) Net Income
The annual net income for Zoetis Inc. (ZTS) is $2.67 Billion with a year-over-year change of +7.52%. Net income represents the company's bottom line profit after all expenses, taxes, and interest.
Annual Net Income (TTM)
$2.67B
$2.67 Billion
Year-over-Year Change
+7.52%
vs. $2.49B prior year
Net Income CAGR
+8.30%
5 Year compound annual growth rate
Net Income CAGR (Compound Annual Growth Rate)
1 Year
+4.97%
3 Year
+8.47%
5 Year
+8.30%
10 Year
+22.19%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Net Income History
| Year | Net Income | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.67B | +$187.00M | +7.52% |
| 2024 | $2.49B | +$142.00M | +6.06% |
| 2023 | $2.34B | +$230.00M | +10.88% |
| 2022 | $2.11B | +$77.00M | +3.78% |
| 2021 | $2.04B | +$399.00M | +24.36% |
| 2020 | $1.64B | +$138.00M | +9.20% |
| 2019 | $1.50B | +$72.00M | +5.04% |
| 2018 | $1.43B | +$564.00M | +65.28% |
| 2017 | $864.00M | +$43.00M | +5.24% |
| 2016 | $821.00M | +$482.00M | +142.18% |
Net Income Growth Summary
TTM Growth
+4.97%
3-Year Avg Growth
+8.47%
5-Year Avg Growth
+8.30%
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck